天津中医药
天津中醫藥
천진중의약
TIANJIN JOURNAL OF TRADITIONAL CHINESE MEDICINE
2004年
5期
426-429
,共4页
药物相互作用%芍药甘草汤%西药%甘草酸%药动学%肠内细菌%代谢活性
藥物相互作用%芍藥甘草湯%西藥%甘草痠%藥動學%腸內細菌%代謝活性
약물상호작용%작약감초탕%서약%감초산%약동학%장내세균%대사활성
drug-drug interaction%Shaoyao-Gancao-Tang%antibacterial drugs%glycyrrhizin%pharmacokinetics: intestinal bacteria
在第Ⅰ部分中,已经报告了芍药甘草汤(SGT)的连续给药提高了SGT中甘草酸(glycyrrhizin,GL)的生物利用度.在本文,即本研究的第Ⅱ部分,对在溃疡治疗中常和SGT合用的西药,如组织胺H2受体拮抗剂 cimetidine,抗胆碱药scopolamine butyl bromide(SBB),由一个质子泵抑制剂(omeprazole,OPZ)和两种抗菌剂 (amoxicillin,AMPC,and metronidazole,MET)所组成的三剂疗法OAM等,对于SGT中GL生物利用度的影响进行了考察.实验结果显示,cimetidine或SBB的合用对SGT中GL的生物利用度没有显著影响,但OAM的合用却有显著的降低作用.OAM降低作用的要因药物经实验证明为抗菌剂组合AMPC-MET,而非质子泵抑制剂 OPZ.AMPC-MET作用的原因机制在于其显著地降低了肠内细菌的将GL代谢成甘草次酸(18β-glycyrrhetic acid,GA)的活性.该结果表明,含有AMPC-MET的三剂疗法如OAM等不适合和SGT同时给药.
在第Ⅰ部分中,已經報告瞭芍藥甘草湯(SGT)的連續給藥提高瞭SGT中甘草痠(glycyrrhizin,GL)的生物利用度.在本文,即本研究的第Ⅱ部分,對在潰瘍治療中常和SGT閤用的西藥,如組織胺H2受體拮抗劑 cimetidine,抗膽堿藥scopolamine butyl bromide(SBB),由一箇質子泵抑製劑(omeprazole,OPZ)和兩種抗菌劑 (amoxicillin,AMPC,and metronidazole,MET)所組成的三劑療法OAM等,對于SGT中GL生物利用度的影響進行瞭攷察.實驗結果顯示,cimetidine或SBB的閤用對SGT中GL的生物利用度沒有顯著影響,但OAM的閤用卻有顯著的降低作用.OAM降低作用的要因藥物經實驗證明為抗菌劑組閤AMPC-MET,而非質子泵抑製劑 OPZ.AMPC-MET作用的原因機製在于其顯著地降低瞭腸內細菌的將GL代謝成甘草次痠(18β-glycyrrhetic acid,GA)的活性.該結果錶明,含有AMPC-MET的三劑療法如OAM等不適閤和SGT同時給藥.
재제Ⅰ부분중,이경보고료작약감초탕(SGT)적련속급약제고료SGT중감초산(glycyrrhizin,GL)적생물이용도.재본문,즉본연구적제Ⅱ부분,대재궤양치료중상화SGT합용적서약,여조직알H2수체길항제 cimetidine,항담감약scopolamine butyl bromide(SBB),유일개질자빙억제제(omeprazole,OPZ)화량충항균제 (amoxicillin,AMPC,and metronidazole,MET)소조성적삼제요법OAM등,대우SGT중GL생물이용도적영향진행료고찰.실험결과현시,cimetidine혹SBB적합용대SGT중GL적생물이용도몰유현저영향,단OAM적합용각유현저적강저작용.OAM강저작용적요인약물경실험증명위항균제조합AMPC-MET,이비질자빙억제제 OPZ.AMPC-MET작용적원인궤제재우기현저지강저료장내세균적장GL대사성감초차산(18β-glycyrrhetic acid,GA)적활성.해결과표명,함유AMPC-MET적삼제요법여OAM등불괄합화SGT동시급약.
In part Ⅰ, we reported that the repetitive administration of Shaoyao-Gancao-Tang (SGT) increased the bioavailability of glycyrrhizin (GL) in SGT. In clinic, SGT is sometimes used together with some synthetic drugs. In this part Ⅱ , the influences of co-administered synthetic drugs on the pharmacokinetic fate of GL from SGT were investigated. The results showed that the co-administration of either a histamine2-receptor antagonist (cimetidine) or an anticholinergic drug (scopolamine butyl bromide, SBB) did not clearly influence the bioavailability of GL in SGT. However, the co-administration of a triple therapy OAM consisting of a proton pump inhibitor (omeprazole, OPZ) and two antibacterial drugs(amoxicillin, AMPC, and metronidazole, MET) markedly reduced the plasma GA concentration. The reduction of plasma GA by OAM was shown to be due to the antibacterial drugs AMPC-MET, not the proton pump inhibitor OPZ. The mechanism of the reduction by AMPC-MET involved the severe decrease of the GL-metabolizing activity of intestinal bacteria by AMPC-MET.These results suggest that it is not appropriate to simultaneously administer AMPC-MET with SGT.
